Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non-small cell lung cancer.
Li DH, He YQ, Wang TM, Xue WQ, Deng CM, Yang DW, Zhang WL, Wu ZY, Cao LJ, Dong SQ, Jia YJ, Yuan LL, Luo LT, Wu YX, Tong XT, Zhang JB, Zheng MQ, Zhou T, Zheng XH, Li XZ, Zhang PF, Zhang SD, Hu YZ, Cao X, Wang X, Jia WH.
Li DH, et al. Among authors: wu zy, wu yx.
Transl Lung Cancer Res. 2022 Sep;11(9):1809-1822. doi: 10.21037/tlcr-22-139.
Transl Lung Cancer Res. 2022.
PMID: 36248337
Free PMC article.